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in part to the general impression that locally recurrent
disease is merely a harbinger of rapidly progressive dis-
tant disease. To date, few series have examined the like-
lihood of survival and local re-recurrence beyond the
perioperative period. To better define a role for surgical
resection of locally recurrent breast cancer, we
reviewed our recent experience at Memorial Sloan-
Kettering Cancer Center.
Patients and methods
A review of the records of the Department of Pathology at
Memorial Sloan-Kettering Cancer Center for the period
October 1987 through April 1997 revealed 38 patients who
underwent surgical resection of the full thickness of the chest
wall in the treatment of locally recurrent breast cancer. These
patients comprised the study group. Clinical information was
obtained through a detailed review of the medical record.
When follow-up information was not available from the hos-
pital record, it was obtained through contact with the patient,
family, or referring physician.
Locally recurrent disease was defined as the reappearance
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of disease on or in the chest wall adjacent to the site of prior
breast excision and not clearly regional recurrence within the
Rotter’s or axillary lymph nodes or sternal hematogenous
metastases. Patients undergoing resection of the chest wall
because of benign disease, such as radionecrosis, or because
of other malignant diseases, such as radiation-induced sarco-
ma, were excluded. Synchronous metastatic disease was
defined as the finding of locoregionally involved lymph
nodes or distant sites of visceral disease and included malig-
nant pleural effusions or implants. Bone invasion was defined
as pathologic invasion into the cortex. A complete resection
(R0) was defined as pathologic demonstration of negative tis-
sue margins and an assessment by the operating surgeon that
all detectable disease had been removed. Patients who had a
complete gross resection and in whom diseased (positive)
margins were found on final pathologic review were classi-
fied as having undergone microscopically incomplete resec-
tions (R1). Gross residual disease after attempted resection
was classified as R2.
Survival probabilities were calculated by the Kaplan-Meier
method from the date of chest wall resection and included
patients who died in the postoperative period (defined as 30
days or less from the day of operation or within the same hos-
pitalization). Time to first evidence of recurrent disease was
calculated from the date of chest wall resection.
Log-rank analysis was used for univariate analysis for sig-
nificant prognostic factors. The following variables were con-
sidered as potentially prognostic variables for survival: pres-
ence of synchronous metastases, presence of lymph node
metastases, R0 versus R1 or R2 resection, number of nodules,
size of largest nodule, presence of bone invasion, and pres-
ence of skin ulceration. Cox regression analysis was used for
multivariable analysis of factors found significant on univari-
ate analysis.
Results
The study population consisted of 38 women with a
median age at chest wall resection of 56 years (range
27-80 years). The histologic type and stage of the orig-
inal breast cancer and the types of treatment are shown
in Table I. The T status of the tumors at first breast
resection was T1 in 3 patients, T2 in 11, T3 in 5, and
could not be defined in 19. The N status at first resec-
tion was N0 in 18 patients, N1 in 7, N2 in 2, and
unknown in 11. The median number of nodes resected
from the axilla was 19 (range 8-33); the number of pos-
Table I. Characteristics of original breast carcinoma
and treatment
No. of patients
Histology
Infiltrating ductal 27
Lobular 3
Cystosarcoma phyllodes 2
Medullary 2
Other 2
Unknown 2
Hormonal status
ER+/PR+ 2
ER–/PR– 9
ER+/PR– 4
Unknown 23
Breast resection
Lumpectomy 14
Modified radical mastectomy 17
Radical mastectomy 6
Simple mastectomy 1
Stage at breast resection
I 6
IIA 11
IIB 5
IIIA 3
Unknown 13
Treatment before chest wall resection
Chemotherapy 9
Radiation therapy 3
Radiation and chemotherapy 12
Hormonal therapy 7
Other 1
None 5
Unknown 1
ER, Estrogen receptor; PR, progesterone receptor.
Table II. Clinical characteristics and operation done
at chest wall resection
No. of patients
Physical examination
Mass without ulceration 28
Mass with ulceration 6
Ulceration without mass 3
Radiographic finding only 1
Sites of metastatic disease
Lung 9
Locoregional lymph nodes 4
Pleura 2
Bone 1
None 22
Extent of chest wall resection
Ribs only 15
Sternum only 1
Sternum and ribs 22
Reconstruction
Marlex mesh-MMA 33
Marlex mesh only 2
PTFE only 1
PTFE/MMA 1
None 1
Skin closure
Primary closure 8
Pedicled myocutaneous flap 25
Free flap 4
Combination of flaps 1
MMA, Methyl methacrylate; PTFE, polytetrafluoroethylene (Gore-Tex mater-
ial; Gore-Tex is a registered trademark of W. L. Gore & Associates, Inc,
Flagstaff, Ariz).
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itive nodes was none in 17 patients, 1 in 3 patients, 2 in
3 patients, 5 in 3 patients, 6 in 1 patient, and unknown
in 11 patients. Overall, 15 patients had received radia-
tion therapy to the chest wall either at the time of orig-
inal breast resection or as an attempt to manage locally
recurrent disease.
The indications for operation and information about
the chest wall resection are shown in Table II. The
median interval from the original breast resection to the
chest wall resection for recurrent disease was 3.6 years
(range 0.4-21 years). Complete re-evaluation for extent
of disease at the time of chest wall resection (including
preoperative and intraoperative evaluation) revealed 16
patients to have metastatic disease either to locoregion-
al lymph nodes or to distant sites. The sites of metasta-
tic disease are listed in Table II.
The number of ribs resected was none in 1 patient, 1 in
1 patient, 2 in 17 patients, 3 in 16 patients, 4 in 4
patients, 5 in 5 patients, 7 in 1 patient, and 8 in 3 patients.
The skin defect after resection was none in 1 patient and
could not be determined from the medical record in 5
patients; in the remaining 32 patients, the median skin
defect after resection was 120 cm2 (range 0-354 cm2).
Biopsy or resection of synchronous metastatic disease
was done in 12 patients. The median length of hospital
stay was 8 days (range 4-31 days). There were no peri-
operative deaths. Four patients had wound complica-
tions, including 2 prosthesis infections (6%) and 2 super-
ficial wound infections (6%). Other complications in the
postoperative period included arrhythmia (1 patient),
requirement for therapeutic bronchoscopy (1 patient),
and intubation beyond 48 hours (1 patient).
The details of pathologic characteristics of the chest
wall specimens are shown in Table III. Examination of
the pathologic specimen suggested that the chest wall
disease consisted of a solitary nodule in 25 patients, 2
nodules in 2 patients, 3 nodules in 3 patients, and 4 or
more nodules in 5 patients. The number of nodules
could not be determined from the pathology report in
the remaining 4 patients. The median size of the largest
nodule was 4 cm (range 1-17 cm). Postoperative treat-
ment was none in 16 patients; external beam radiation
therapy in 3; chemotherapy in 9; chemotherapy and
radiation therapy in 2; stem cell transplantation in 1;
hormonal treatment alone in 3; monoclonal antibody
treatment in 1; and unknown in 3.
The first site of recurrent disease in the patients ren-
dered free of disease by chest wall resection was local
in 7, lung or pleura in 6, unknown in 5, brain in 4, axil-
la in 3, and bone in 2. At the time of last follow-up, 24
patients (63%) had no evidence of local recurrence.
Overall survival and survival stratified by presence of
synchronous metastases are presented in Figs 1 and 2.
Survival analyses were repeated excluding the 2
patients with cystosarcoma phyllodes, and there was no
difference in survival compared with the overall group
(data not shown). Freedom from local recurrence is
shown in Fig 3.
Table IV provides the results of univariate analyses
of variables in relationship to survival and local recur-
rence in all patients. The presence of regional lymph
node metastases (most often internal mammary) was
the only significant prognostic factor for overall sur-
vival. Both regional lymph node metastases and the
size of the largest nodule (>4 cm) had a significant
impact on local recurrence.
Discussion
The rate of locally recurrent breast cancer after
apparently complete excision of stage I or II disease is
thought to be between 4% and 20%.1-3 Isolated local
recurrences represent 20% of all recurrences, and local
disease in combination with either regional (usually
lymph node) or distant recurrences represents a further
3%.3 The reappearance of disease on the chest wall is
considered to predict a poor prognosis, with 5-year sur-
vival frequently estimated to be 30% to 50%,4,5 and
mortality is attributed to the frequent subsequent
appearance of disseminated metastases. However, a
detailed analysis of isolated chest wall recurrences sug-
gested that local recurrence was associated with a
median survival of 5.6 years and a 10-year survival of
30%.6 Therefore the precise natural history of this
problem is not fully defined.
It must be kept in mind that patients undergoing chest
wall resection for breast cancer probably represent a
distinct group within the population of patients with
recurrent breast cancer on the chest wall. Most locally
recurrent breast cancers consist of disease reappearing
Table III. Pathologic characteristics of chest wall
specimens
Yes No Unknown
Lymph node metastases 9 (24%) 29 (76%) 0
Complete resection of 30 (79%) 8 (21%) 0
gross local disease (R0)
More than 1 nodule 9 (25%) 25 (74%) 4
Largest nodule >4 cm 16 (50%) 16 (50%) 6
Bone invasion 14 (45%) 17 (55%) 7
Pathologic margins 8 (25%) 23 (75%) 7
positive (R1)
Skin ulcer 10 (33%) 20 (67%) 8
Data are given as the number of patients, with the percentage of these patients
among those with available information given in parentheses.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 3
Downey et al 423
only within the mastectomy/lumpectomy skin incision
or within the area of dissection, such as the skin flaps.
Patients requiring chest wall resection for the manage-
ment of locally recurrent breast cancer probably have a
more extensive burden of disease, as it is possible, even
likely, that the group of patients undergoing chest wall
resection includes patients not only with truly local (ie,
soft tissue only) recurrence, but also those with disease
progressing from involved internal mammary lymph
nodes or from hematogenous spread to the sternum.
Therefore comparison of patient groups requiring chest
wall resection with series of patients treated for soft tis-
sue recurrence alone may be misleading.
No matter the extent of local disease, the goals of
management include relief of pain or resolution of per-
sistent infections, removal of unsightly fungating
lesions, prevention of skin breakdown before chemo-
therapy, and, possibly, improved survival by the
removal of the only known site of disease. Treatment to
achieve one or more of these goals is often highly indi-
vidualized and can include surgical resection, radiation
therapy, chemotherapy, or some combination of these
treatments. Dahlstrom and colleagues7 reported a 45%
rate of second local recurrence after surgical resection
of soft tissues alone, without a chest wall resection.
Similarly, Probstfeld and O’Connell4 found re-recur-
Fig 1. Overall survival from date of first chest wall resection, all patients (n = 36, which excludes 2 patients with-
out survival data).
Fig 2. Overall survival from date of first chest wall resection, all patients stratified by presence of synchronous
metastases (Sync Mets).
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rence rates after radiation therapy alone to be 83%,
after resection of soft tissues alone to be 62%, and after
combination surgical treatment and radiation therapy to
be 25%. Importantly, Halverson and associates8 noted
100% control with 6000 cGy of lesions that either
could be completely excised or were less than 3 cm in
diameter. However, only half of the lesions measuring
more than 3 cm could be controlled by radiation, even
with doses of irradiation up to 7000 cGy. Thus it
appears that control of local recurrences may be relat-
ed to the depth of surgical resection (ie, adequacy of
deep margins) and to the size of the lesions, especially
when radiation is the main treatment.
Before acceptance of full-thickness chest wall resec-
tion as a practical extension of excision of soft tissues,
it must be demonstrated that, first, the procedure can be
done safely, and, second, the procedure achieves the
goal of either palliation or cure. Chest wall resection
Fig 3. Time to local recurrence after chest wall resection, all patients (n = 36, which excludes 2 patients without
recurrence information).
Table IV. Univariate and multivariable analysis of prognostic factors for survival and local recurrence after chest
wall resection for locally recurrent breast carcinoma
Overall survival 
Overall survival (all patients) (excludes 2 cystosarcoma) Risk of local recurrence
Multivariable Multivariable Multivariable 
Univariate Cox model Univariate Cox model Univariate Cox model
P value, Risk ratio & P value, Risk ratio & P value, Risk ratio & 
Variable log-rank P value 95% CI log-rank P value 95% CI log-rank P value 95% CI
Synchronous metastases
No
Yes .12 .18 .08
Lymph nodes
Negative
Positive <.01 .02 2.8 (1.2, 6.8) .02 .03 2.7 (1.1, 6.7) <.01 <.01 20 (3, 130)
No of nodules
1
>1 .06 .07 2.3 (.95, 5.5) .13 .41
Size
≤4
>4 1 .83 <.01 <.01 9 (2, 43)
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with immediate plastic reconstruction is well docu-
mented to be safe in the management of primary lung
cancers and primary chest wall tumors, as well as other
benign and malignant thoracic diseases. The primary
concern after any chest wall resection is the adequacy
of respiratory function after disruption of the structural
integrity of the bony thorax. At Memorial Sloan-
Kettering Cancer Center, we commonly use a rigid
prosthesis, usually a sandwich of Marlex mesh–methyl
methacrylate, first devised by Dr Manjit Bains in
1981,9 with very acceptable results. In large series of
patients, the ability to restore rigidity to the chest wall
has led to a low and acceptable rate of use of postoper-
ative mechanical ventilatory support in the range of less
than 13%.9,10 Similarly, chest wall resection has been
shown to carry an acceptable risk of perioperative mor-
tality of 3% to 4.5%.9,10
Previously published series of patients undergoing
resection of recurrent breast cancer invading the bony
structures of the chest wall suggest that the operative
morbidity and mortality seen are similar to or better than
the results when the operation is done for other disease
processes. For example, Miyauchi,11 Toi,12 Faneyte,13
and their colleagues reported on a total of 92 patients
with an overall operative mortality rate of 0%. Our
results are similar with a perioperative mortality rate of
0%, median length of hospital stay of 8 days, and only 1
patient requiring prolonged mechanical ventilation.
The second problem encountered is that of closure of
a soft tissue defect in a scarred, often irradiated field.
The size of the defects created can be impressive,
because incision into the contracted tissues can lead to
relaxation with creation of defects considerably larger
than the measurements taken from pathologic speci-
mens. However, the progress made in the field of
reconstructive surgery with tissue transfer techniques
(most commonly in our series, a vascularized pedicled
muscle flap), as recently reviewed by Arnold and
Pairolero,10 has led to the expectation on the part of sur-
geons that the majority of defects can be closed without
incurring significant additional morbidity. In our series,
we had 4 wound complications, including 2 prosthesis
infections (6%) and 2 superficial wound infections
(6%), which appears to be a reasonable rate of wound
complications for the operations involved. Major com-
plications such as flap necrosis were not seen.
If full-thickness resection of the chest wall can be
done with acceptable morbidity and mortality, the sec-
ond concern is the adequacy of palliation and the dura-
tion of survival. Several recent series have documented
excellent results on both of these counts. For example,
Miyauchi and colleagues11 reported in 1992 on 23
patients (all with isolated chest wall recurrences) with
5-year local relapse-free rates of 66% and a survival of
48%. Similarly, Toi and colleagues12 in 1997 reported
on 15 patients with isolated chest wall disease with a 5-
year local relapse-free rate of 74% and a 5-year sur-
vival of 47%, and Faneyte and colleagues13 in 1997
recorded 44 patients with isolated chest wall disease
with a 5-year survival of 45% and a rate of freedom
from local relapse of 80%. Our results support these
previous papers with the finding of survival in patients
without synchronous disease at 1 year of 71%, at 3
years of 42%, and at 5 years of 35% and a rate of free-
dom from local failure at time of death or last follow-
up of approximately 60%.
Our results extend those of these previous studies by
allowing comparison between patients with and with-
out synchronous metastatic disease. We found the pres-
ence or absence of synchronous distant metastases to
not be significantly associated with survival because 3-
year survival estimates were similar for both groups at
approximately 40%. Even though some patients oper-
ated on in the absence of metastatic disease survived
for 5 years, whereas no patient operated on in the pres-
ence of metastatic disease survived for 5 years, our
results have to be taken to suggest that resection of
chest wall disease is unlikely to confer a survival
advantage even for those patients without evidence of
other sites of disease and should be done for palliative
Table V. One-, three-, and five-year Kaplan-Meier survival estimates
Overall survival (Fig 2)
Overall survival Time to local 
(Fig 1) Synchronous metastases recurrence (Fig 3)
Overall No Yes Overall
1 y 0.74 (0.61, 0.90) 0.71 (0.54, 0.94) 0.79 (0.60, 1.00) 0.59 (0.45, 0.78)
3 y 0.41 (0.27, 0.63) 0.42 (0.24, 0.73) 0.39 (0.20, 0.77) 0.42 (0.26, 0.66)
5 y 0.18 (0.08, 0.41) 0.35 (0.18, 0.68) 0.13 (0.03, 0.63)
95% CIs are shown in parentheses.
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reasons only. However, the quality of palliation appears
satisfactory, because 60% of patients were free of local
re-recurrence at death or last follow-up, and some of
the second recurrences may have been less troublesome
than the first.
Various prognostic factors have been suggested to
assist in the selection of patients for surgical resection,
including degree of lymph node involvement at time of
original resection, size of original breast tumor, interval
from breast resection to local recurrence, and patholog-
ic characteristics of the local recurrence such as size
and number of nodules and presence of lymphangitic
spread or involved lymph nodes.4,14-16 Information on
T and N status at the time of original breast resection,
as well as the appearance of possible lymphangitic
spread at the time of chest wall recurrence, could not be
reliably determined from our records, and therefore
these were not evaluated as possible prognostic vari-
ables. The prognostic factors we identified for likeli-
hood of achieving local control and overall survival
appear of limited value. For a surgeon, the helpfulness
of knowing that involved regional lymph nodes indi-
cate a poorer prognosis is unclear, because it is likely
that it will be impossible to obtain biopsy specimens of
these nodes before operating. Similarly, the finding that
larger lesions are more likely to re-recur locally seems
unlikely to deter an attempt at resection for palliation.
In conclusion, from these data and previous publica-
tions, it is clear that full-thickness resection of the chest
wall can be done with acceptable morbidity and mortal-
ity, and, as best as can be determined from a retrospec-
tive study, it is likely that full-thickness resection of the
chest wall for recurrent breast cancer offers significant
palliation for the patient with locally recurrent disease.
Surgical resection with the goal of palliation can be con-
sidered, even with multiple nodules, skin ulceration,
and distant metastatic disease, if other modes of therapy
have failed in a patient. Given the decreasing effective-
ness of radiation therapy in controlling lesions of sizes
greater than 3 cm, surgical resection may be considered
as an alternative primary therapy. Unfortunately, it
appears unlikely that survival is improved with the
resection of all known chest wall disease, even in the
absence of any known distant metastatic disease.
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Discussion
Dr Mark S. Allen (Rochester, Minn). Patients with recur-
rent breast cancer in the chest wall can be difficult to treat.
They often have large, painful lesions that usually ulcerate
and cause disabling symptoms. I thank the authors for giving
us some useful information related to this problematic group
of patients. Whereas others have tried chemotherapy or radi-
ation therapy, these authors have chosen to use surgical resec-
tion with modern plastic surgical reconstruction. They seem
to have provided excellent palliation in the majority of
patients, with only minimal morbidity.
I have several questions. In the manuscript you report a
35% incidence of positive pathologic margins, including 1 in
5 patients with a grossly positive margin. This apparently did
not affect outcome. What do you use as a guide for resec-
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tion margins? Do you just remove the main mass? Is a 1-cm
margin enough, or should we try for a larger margin?
You also reported that two thirds of the patients had skin
ulceration, which presumably means that there was infection
present. Despite the infection, you chose to use an artificial
material for reconstruction in almost every patient and had a
postoperative infection rate in 13% of patients. How did you
manage the infection with Marlex mesh–methyl methacrylate
present? Do you do anything at the initial excision to reduce
the risk of infection?
Finally, this is obviously a selected group, since I am sure
that the Memorial Sloan-Kettering group sees more than 38
women with recurrent breast cancer over a 10-year period.
What can you tell us about your selection criteria for this
operation? What factors do you look at to decide when to
treat these patients with resection and reconstruction?
Dr Downey. Starting first with the selection question, the
impetus for this study was that the breast oncology service
did not believe that we could do the operation with a very low
morbidity and mortality. They also did not believe there was
any survival benefit. I think that this study shows that they
were wrong on the first count and right on the second. The
patients were only rarely referred to us previously, but prob-
ably now we will see more and refine our selection criteria
further. Currently, after completing this study, we will do this
operation for palliative goals but without an attempt to
improve survival.
To return to the first question about margins: Micro-
scopically positive margins were seen in 8 patients and gross
resection of disease was done in all patients. The finding of
microscopically positive margins in only 8 patients is low and
surprising. These patients are usually heavily irradiated,
scarred, and often superinfected and it can be extremely dif-
ficult to know whether a resection margin is across tumor and
scar tissue. I perform multiple biopsies of any tissue in which
there is a question, but I was surprised at what appeared to be
a low number of final positive margins.
In terms of the prosthetic material that is used, patients with
infections are brought into the hospital several days in advance
with the intent to give them antibiotics and local wound care.
If cellulitis appears to be controlled with that, they are taken to
the operating room for a wide resection back to what appears
to be clean tissue. We have not had a high infection rate.
Wound infection complications occurred in 4 patients, 2 of
whom had superficial cellulitis and 2 of whom had prosthetic
infections. I do not know whether the prostheses had to be
removed. If a patient has a wound with unrelenting infection
despite all measures, we may forego the placement of any
prosthetic material, particularly if we can use a rectus abdo-
minis myocutaneous flap, because this provides a fairly stable
amount of support to the chest wall with minimal flail.
Dr Joseph S. Friedberg (Philadelphia, Pa). Because the
treatment had no impact on survival, I guess you could term
this a quality-of-life operation. Was there any assessment
done of the patients’ postoperative quality of life and any sort
of interview or assessment made to see whether, in retrospect,
you think that this was the correct thing to do?
Dr Downey. This was a purely retrospective study, and we
had difficulty even assessing whether recurrences actually
occurred, let alone assessing quality of life. It is entirely pos-
sible that adequate palliation could be achieved even if a
recurrence subsequently developed, if the recurrence was less
onerous than the original recurrence. That information is not
available to us from a retrospective study and would require
a prospective study.
Dr Steven J. Mentzer (Boston, Mass). I would like to ask
a question to clarify the indications for the operation. If
lymph node involvement and the number of nodules are poor
predictors of outcome, there must be a point at which local-
ized disease becomes too extensive for resection. I do not
think anyone would propose that carcinoma en cuirass is a
resectable lesion. On the basis of your study, do you have any
guidelines regarding the extent of lymphatic invasion and the
indications for operation?
Dr Downey. I doubt that patients with clear lymphangitic
spread against the chest wall were ever brought to surgical
treatment. That is a point that was made well in Dr
McKenna’s paper from M.D. Anderson several years ago.
The value of knowing that lymph node involvement portends
a poor prognosis is unclear. These are nodes that are general-
ly only available for biopsy by the time a major portion of the
operation has been completed, usually after division of the
sternum. Therefore, when I have found involved nodes, I have
continued to finish the operation. It does, though, I think,
imply with most patients, even with just evidence for a soft
tissue recurrence, there is a lymphangitic component and
probably diffuse lymphatic disease.
Dr Valerie W. Rusch (New York, NY). I would like to add
a couple of comments. With respect to quality of life, I
think that any thoracic surgeon will know that the quality-
of-life benefit brought by resection to a woman who has
locally recurrent breast cancer, particularly after radiation
to the chest wall, is clear without a quality-of-life study.
This is a horrible, painful problem, and patients are grate-
ful for having the tumor removed. We are never going to be
able to quantify the impact on quality of life because even
in major cancer centers, the patient population is heteroge-
neous and relatively small. However, anyone who has treat-
ed these patients as a clinician will understand the impor-
tance of surgical resection in the management of this
problem.
The other point that warrants emphasis is that the breast
oncologists often are unsure whether patients who have had
this operation should receive additional treatment. One of the
conclusions from our experience is that patients who have
lymphatic involvement clearly require additional systemic
treatment.
Dr Thomas R. J. Todd (Toronto, Ontario, Canada). Obvi-
ously, if you have placed prosthetic material, infection is
important. You only had 3 cases, so I know you cannot draw
specific conclusions. However, I do have two questions. First,
did the infections occur in the women who had a breakdown
of the skin preoperatively? Second, in that situation, either
with breast cancer or with osteoradionecrosis, do you have an
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antibiotic prophylaxis regimen or any preoperative regimen
to prevent infection when you are going to use prosthetic
material in the chest wall?
Dr Downey. I do not know whether the wound infections
and the prosthetic infections occurred in patients with overly-
ing ulcers. The majority of these patients had masses without
overlying skin ulcers, so I do not know how well I can com-
ment on how to treat patients with ulceration. We will give
preoperative antibiotics, but not a standard regimen. We are
currently reviewing a larger series of patients, numbering
almost 75, who have had full-thickness chest wall resections
for other diseases, such as osteoradionecrosis. We hope this
will give us better answers.
Dr Mark B. Orringer (Ann Arbor, Mich). Can I ask the
number of these patients in whom hormonal therapy failed?
Thoracic surgeons generally view chest wall tumors as a sur-
gical disease, and chemotherapy as a rule has not much to
offer for most chest wall tumors. However, metastatic breast
cancer is not the standard chest wall tumor that we see in our
practices, and hormonal therapy, a different kind of chemo-
therapy, may have a real role here. I had experience with a
patient who 9 years after a mastectomy had chest wall and
cutaneous nodules on the operative side. I planned a rather
heroic chest wall resection and reconstruction, but before this
intervention she was treated with tamoxifen. The chest wall
and cutaneous lesions regressed and disappeared, and within
3 months there was not a cutaneous or chest wall lesion left.
She lived another 5 years. Additionally, now there is the next
generation of hormonal therapy: anastrozole (Arimidex).
Does your algorithm for resection follow failure of these hor-
monal agents to work first?
Dr Downey. In our series, 7 women had received hormon-
al therapy at some point between the original breast operation
and immediately before chest wall resection. As I said, the
breast oncologists are reluctant to refer these patients at this
point. I think it is fair to say that they exhaust everything they
consider reasonable options, and I am sure that this now
includes hormonal therapy.
